FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Tumor-Infiltrating Lymphocyte Abundance Prognostic in Early-Stage TNBC
THURSDAY, April 18, 2024 -- For patients with early-stage triple-negative breast cancer (TNBC) who undergo surgery without chemotherapy, tumor-infiltrating lymphocyte (TIL) abundance is associated with improved survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2024 Category: Pharmaceuticals Source Type: news
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
The PROACT trial assessing enalapril in patients with cancer undergoing chemotherapy showed this approach did not affect cardiac function or the rate of cardiac injury.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 18, 2024 Category: Internal Medicine Tags: Cardiology News Source Type: news
Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant
WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC). The data showed that Imfinzi plus standard-of-care chemotherapy demonstrated a clinically…#astrazenecaplcazn #topaz1phase3 #imfinzi #topaz1 #median #azn (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2024 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Investor Update - April 15, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Media News - April 15, 2024 Category: Pharmaceuticals Source Type: news
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
FRIDAY, April 12, 2024 -- Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2024 Category: Pharmaceuticals Source Type: news
St James ’ Hospital rolls out robot to make cancer drugs
The hospital is using a new robot to boost productivity and a cancer patient recently received a treatment made by this robot. Robots are making their move into the medical sector, as the Trinity St James’s Cancer Institute at St James’ Hospital is using a robot to make chemotherapy drugs. The…#stjameshospital #institute #stjamess #ireland #chemotherapy #stjamesshospital #gailmelanophy #lizhogan #irish #akara (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer
(MedPage Today) -- SAN DIEGO -- A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer in a small pilot study, a researcher reported here.
In the phase I/II trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 11, 2024 Category: Gastroenterology Source Type: news
Combo Therapy Prolongs Survival in Gastric Cancer Patients Combo Therapy Prolongs Survival in Gastric Cancer Patients
The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
UltraCon: Harmonic motion imaging tracks breast tumor response to chemo
AUSTIN -- Harmonic motion imaging can track mechanical property changes of breast tumors in response to neoadjuvant chemotherapy, a study presented April 9 at UltraCon found.
In his presentation, Yangpei Liu from Columbia University in New York City discussed findings from his team’s study, which showed that harmonic motion imaging could be a predictor of early treatment response.
“Harmonic motion imaging-derives changes in tumor mechanical properties are more robust in early complete pathologic response prediction than tumor sizes,” Liu said.Yangpei Liu from Columbia University in Ney York City discussed findings ...
Source: AuntMinnie.com Headlines - April 10, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Womens Imaging Source Type: news
I endured aggressive chemo and said goodbye to my family after being given just 15 months to live - only to discover I never had cancer
Lisa Monk, from College Station in Texas, endured 'aggressive' chemotherapy and said goodbye to her family after being given just 15 months to live - only to discover she never had cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - April 9, 2024 Category: Consumer Health News Source Type: news
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 -- For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2024 Category: Pharmaceuticals Source Type: news
